Severe Hypertriglyceridemia clinical trials

Explore recruiting severe hypertriglyceridemia clinical trials.

Recruiting severe hypertriglyceridemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Severe Hypertriglyceridemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-3 Study)

Poland, Belgium, Czechia, Spain, Slovakia, Croatia +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-4 Study)

Poland, Lithuania, Slovakia, Spain, Germany, Hungary +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia (SHTG)

Spain, Poland, Hungary, Latvia, Austria, Bulgaria +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia (SHTG)

Bulgaria, Hungary, Poland, France, Spain, Czechia +13 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

ISIS 678354-CS5: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia.

Finland, Germany, Poland, Sweden, Slovakia, Hungary +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

ISIS 678354-CS6 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia

France, Italy, Hungary, Belgium, Poland, Slovakia +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Severe Hypertriglyceridemia trials by city

Severe Hypertriglyceridemia in Toronto Severe Hypertriglyceridemia in Vancouver Severe Hypertriglyceridemia in Montreal Severe Hypertriglyceridemia in Calgary Severe Hypertriglyceridemia in Edmonton Severe Hypertriglyceridemia in Ottawa Severe Hypertriglyceridemia in Winnipeg Severe Hypertriglyceridemia in Quebec City Severe Hypertriglyceridemia in Hamilton Severe Hypertriglyceridemia in Kitchener Severe Hypertriglyceridemia in London Severe Hypertriglyceridemia in Halifax Severe Hypertriglyceridemia in New York Severe Hypertriglyceridemia in Los Angeles Severe Hypertriglyceridemia in Chicago Severe Hypertriglyceridemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease